Abstract:The repertoire of currently available antiviral drugs spans therapeutic applications against a number of important human pathogens distributed worldwide. These include cases of the pandemic severe acute respiratory coronavirus type 2 (SARS-CoV-2 or COVID-19), human immunodeficiency virus type 1 (HIV-1 or AIDS), and the pregnancy- and posttransplant-relevant human cytomegalovirus (HCMV). In almost all cases, approved therapies are based on direct-acting antivirals (DAAs), but their benefit, particularly in long-term applications, is often limited by the induction of viral drug resistance or side effects. These issues might be addressed by the additional use of host-directed antivirals (HDAs). As a strong input from long-term experiences with cancer therapies, host protein kinases may serve as HDA targets of mechanistically new antiviral drugs. The study demonstrates such a novel antiviral strategy by targeting the major virus-supportive host kinase CDK7. Importantly, this strategy focuses on highly selective, 3D structure-derived CDK7 inhibitors carrying a warhead moiety that mediates covalent target binding. In summary, the main experimental findings of this study are as follows: (1) the in vitro verification of CDK7 inhibition and selectivity that confirms the warhead covalent-binding principle (by CDK-specific kinase assays), (2) the highly pronounced antiviral efficacies of the hit compounds (in cultured cell-based infection models) with half-maximal effective concentrations that reach down to picomolar levels, (3) a particularly strong potency of compounds against strains and reporter-expressing recombinants of HCMV (using infection assays in primary human fibroblasts), (4) additional activity against further herpesviruses such as animal CMVs and VZV, (5) unique mechanistic properties that include an immediate block of HCMV replication directed early (determined by Western blot detection of viral marker proteins), (6) a substantial drug synergism in combination with MBV (measured by a Loewe additivity fixed-dose assay), and (7) a strong sensitivity of clinically relevant HCMV mutants carrying MBV or ganciclovir resistance markers. Combined, the data highlight the huge developmental potential of this host-directed antiviral targeting concept utilizing covalently binding CDK7 inhibitors.

[New drug targets of herpesviruses]

Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection

Natural Products and Their Derivatives against Human Herpesvirus Infection

HBV life cycle and novel drug targets

Receptors and ligands for herpes simplex viruses: Novel insights for drug targeting

Anti-virus reagents targeting the capsid protein assembly

Current Progress in Antiviral Strategies.

Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents

Toll‐like Receptors As Novel Therapeutic Targets for Herpes Simplex Virus Infection

Combined Effect of Basic Antiherpetic Drugs with a New Inhibitor of the Terminase Complex of Herpes Simplex Virus Type 1 in Vero Cell Cultures

Anti-herpes simplex virus activities and mechanisms of marine derived compounds

A review of HSV pathogenesis, vaccine development, and advanced applications

An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity

Antivirals against human polyomaviruses: Leaving no stone unturned

Host targeted antiviral (HTA): functional inhibitor compounds of scaffold protein RACK1 inhibit herpes simplex virus proliferation

Small Molecule Drugs Targeting Viral Polymerases

A Route to Novel Antiviral Agents and New Therapeutic Approaches

Systematic Optimization of Host-Directed Therapeutic Targets and Preclinical Validation of Repositioned Antiviral Drugs

Identifying HSV-1 Inhibitors from Natural Compounds via Virtual Screening Targeting Surface Glycoprotein D

Antivirals with common targets against highly pathogenic viruses

Directions for the Development of CRISPR/Cas-Based Therapeutics and Diagnostics